Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: A phase II trial

Haematologica

Volumn 90, Issue 12, 2005, Pages 1650-1654

  Dingli, David ^a   Rajkumar, S Vincent ^a   Nowakowski, Grzegorz S ^a   Gertz, Morie A ^a   Dispenzieri, Angela ^a   Lacy, Martha Q ^a   Hayman, Suzanne ^a   Fonseca, Rafael ^a   Lust, John A ^a   Kyle, Robert A ^a   Greipp, Philip R ^a   Witzig, Thomas E ^a  

^a Mayo Clinic   (United States)

Author keywords

Dexamethasone; Multiple myeloma; Thalidomide; Therapy

Indexed keywords

DEXAMETHASONE; THALIDOMIDE;

ADULT; AGED; AGEISM; ANXIETY DISORDER; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEEP VEIN THROMBOSIS; DIZZINESS; DOSE RESPONSE; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HUMAN; INNER EAR DISEASE; LUNG EMBOLISM; MALE; MULTIPLE MYELOMA; NEUROPATHY; PARESTHESIA; PHASE 2 CLINICAL TRIAL; SEDATION; SIDE EFFECT; SYNCOPE; THROMBOSIS; TOXICITY; TREATMENT OUTCOME; TREMOR; TUMOR DIAGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE MANAGEMENT; CLINICAL TRIALS, PHASE II; COHORT STUDIES; CONSTIPATION; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; EDEMA; FATIGUE; FEMALE; HUMANS; LIFE TABLES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PARESTHESIA; REMISSION INDUCTION; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 29144480867     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kyle RA. Diagnosis of multiple myeloma. Semin Oncol 2002;29:2-4.
2. Cheung WC, Van Ness B. The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro. Leukemia 2001;15:264-71.
3. Dalton WS. The tumor microenvironment: focus on myeloma. Cancer Treat Rev 2003; 29 Suppl 1:11-9.
4. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
5. Rajkumar SV, Kyle RA. Angiogenesis in multiple myeloma. Semin Oncol 2001; 28:560-4.
6. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
7. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, et al. Thalidomide in the treatment of relapsed multiple myeloma. Mayo Clin Proc 2000; 75:897-901.
8. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol 2001;28:597-601.
9. Harousseau JL, Attal M, Divine M, Marit G, Leblond V, Stoppa AM, et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma. Stem Cells 1995;13 Suppl 2:132-9.
10. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
11. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am J Hematol 1990;33: 86-9.
12. Johnson RJ, Owen RG, Smith GM, Child JA, Galvin M, Newton LJ, et al. Peripheral blood stem cell transplantation in myeloma using CD34 selected cells. Bone Marrow Transplant 1996;17:723-7.
13. Friedenberg WR, Kyle RA, Knospe WH, Bennett JM, Tsiatis AA, Oken MM. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol 1991;36:171-5.
14. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80: 887-90.
15. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002;20:4319-23.
16. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003;21:16-9.
17. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004;89:826-31.
18. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.
19. Ghobrial IM, Dispenzieri A, Bundy KL, Gastineau DA, Rajkumar SV, Therneau TM, et al. Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma. Bone Marrow Transplant 2003;32:587-92.
20. Harousseau JL. High-dose therapy in multiple myeloma. Ann Oncol 2002;13 Suppl 4: 49-54.
21. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT European Group for Blood and Marrow Transplant. Br J Haematol 1998;102: 1115-23.
22. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
23. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-17.
24. Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, et al. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica 2004; 89:1124-7.
25. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-502.
26. Harousseau JL, Attal M. High-dose therapy in multiple myeloma. Hematol J 2003;4: 163-70.
27. Bergsagel DE, Bailey AJ, Langley GR, MacDonald RN, White DF, Miller AB. The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979;301:743-8.
28. Cooper MR, McIntyre OR, Propert KJ, Kocnwa S, Anderson K, Coleman M, et al. Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study. J Clin Oncol 1986;4:1331-9.
29. Boccadoro M, Marmont F, Tribalto M, Avvisati G, Andriani A, Barbui T, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444-8.
30. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BG, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1983;1:453-61.
31. Mileshkin L, Biagi JJ, Mitchell P, Underhill C, Grieg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69-77.
32. Attal M, Harousseau JL, Leyvraz L, Doyen D, Hulin C, Benboubker L, et al. Maintenance treatment with thalidomide after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myelome (IFM 99 02). Haematologica 2005; 90 Suppl 1:17.
33. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001;98:1614-5.
34. Zangari M, Barlogie B, Thertulien R, Jacobson J, Eddleman P, Fink L, et al. Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival. Clin Lymphoma 2003;4:32-5.
35. Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-21.
36. Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Cangialosi C, et al. Prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood 2004;104:270a[Abstract].